101 completed, 10 terminated, 5 withdrawn, 4 active not recruiting. 37 Phase 3, 31 Phase 4, 30 Phase 2, 15 Phase 1, 6 Not applicable.
Follow Fluticasone Propionate: new trials by email Literature Review of Fluticasone Propionate trials Research Report on Fluticasone Propionate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Novel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate Fluticasone Propionate, Water Mouthwash, EVOOW Mouthwash - Asthma | Phase 4 | Not yet recruiting | University of Wisconsin, Madison | 20 | 2026-11-01 | 2026-09-24 |
| A Study to Visualize Multi-Symptom Allergy in Adults With Seasonal Allergic Rhinitis Fluticasone propionate - Rhinitis Allergic, Rhinitis Seasonal | Phase 4 | Not yet recruiting | HALEON | 16 | 2026-09-01 | 2026-09-14 |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma Fp/ABS, FP, ABS - Asthma | Phase 3 | Active not recruiting | Teva Branded Pharmaceutical Products R&D LLC | 649 | 2024-12-12 | 2026-10-06 |
| BElumosudil for Bronchiolitis Obliterans Prevention/Therapy (BEBOP) Belumosudil, Fluticasone, Azithromycin - Bronchiolitis Obliterans Syndrome, Bronchiolitis Obliterans | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 45 | 2024-05-31 | 2026-06-10 |
| Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab - Skin Inflammation, Allergic Contact Dermatitis | Phase 2 / Phase 3 | Active not recruiting | Wei-Che Ko | 45 | 2022-11-15 | 2026-06-09 |
| A Study Comparing the Efficacy of Pataday® Once Daily Relief Extra Strength to Flonase® Allergy Relief in Subjects With Allergic Conjunctivitis olopatadine hydrochloride ophthalmic solution 0.7%), Fluticasone Propionate, Tears Naturale - Allergic Conjunctivitis | Phase 4 | Completed | Andover Research Eye Institute | 61 | 2021-12-31 | 2022-09-02 |
| Cycling of Topical Steroids for Treatment of EoE (Eosinopilic Esophagitis) Fluticasone Propionate, Budesonide - Eosinophilic Esophagitis | Phase 4 | Completed | University Hospitals Cleveland Medical Center | 23 | 2021-11-17 | 2024-11-07 |
| Efficacy and Safety APT-1011 in Adolescent Subjects With Eosinophilic Esophagitis (EoE) - A Sub-Study of the FLUTE-2 Trial APT-1011, Placebo oral tablet - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 6 | 2021-09-30 | 2023-09-21 |
| FLuticasone in cOvid Treatment (FLOT) Fluticasone Propionate - Covid19 | Phase 2 / Phase 3 | Unknown | University of Medicine and Pharmacy at Ho Chi Minh City | 500 | 2021-09-22 | 2021-09-23 |
| Allergic Rhinitis Combination Pharmacotherapy Efficacy Study Fluticasone Propionate, Azelastine hydrochloride and fluticasone propionate, Rupatadine - Allergic Rhinitis | Phase 4 | Withdrawn | St. Paul's Sinus Centre | 2020-12-15 | 2023-10-31 | |
| Hypertonic Versus Isotonic Saline Irrigations for Chronic Rhinosinusitis Isotonic saline, Hypertonic Nasal Wash, Fluticasone Propionate - Chronic Rhinosinusitis (Diagnosis) | Phase 2 / Phase 3 | Withdrawn | Stanford University | 2020-07-01 | 2021-03-18 | |
| Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2) APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy - Eosinophilic Esophagitis | Phase 3 | Completed | Ellodi Pharmaceuticals, LP | 143 | 2020-01-30 | 2023-06-12 |
| Study Evaluating the Safety and Tolerability of NCX 4251 for the Treatment of Acute Exacerbations of Blepharitis Fluticasone Propionate, Placebo - Blepharitis | Phase 2 | Completed | Nicox Ophthalmics, Inc. | 36 | 2019-03-18 | 2023-06-18 |
| Efficacy & Safety of OPN-375 Adults With Bilateral Nasal Polyps Using Nasoendoscopic Video Fluticasone Propionate - Nasal Polyposis | Phase 3 | Completed | Optinose US Inc. | 11 | 2018-06-07 | 2020-08-03 |
| Personalized Treatment Algorithms for Difficult-to-treat Asthma Cholecalciferol, antihistamine, Azithromycin - Asthma in Children | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 21 | 2018-03-16 | 2021-08-20 |
| A Study to Evaluate Changes in Nasal Airflow of Loratadine/Pseudoephedrine Tablet and Fluticasone Propionate Nasal Spray in Subjects Following Allergen Exposure loratadine + pseudoephedrine sulfate (BAY818725/Claritin-D), Placebo tablet, Fluticasone Propionate - Rhinitis, Allergic | Phase 4 | Completed | Bayer | 82 | 2018-02-21 | 2019-12-20 |
| Post-marketing Safety Monitoring Program of Fluticasone Propionate (FP) in Chinese Subjects With Asthma Aged 1 to <4 Years Fluticasone propionate - Asthma | Completed | GlaxoSmithKline | 158 | 2018-01-09 | 2019-10-02 | |
| Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma GSK3772847, Placebo, Fluticasone propionate/salmeterol - Asthma | Phase 2 | Completed | GlaxoSmithKline | 165 | 2017-09-14 | 2020-03-02 |
| The ENERGITO® 2 Study Compares 2 Inhaled Medicines for Chronic Obstructive Pulmonary Disease (COPD). One Medicine is a Combination of Tiotropium and Olodaterol (Stiolto®) Taken Using the Respimat® Inhaler and the Other Medicine is a Combination of Fluticasone and Salmeterol Taken Using the Diskus Tiotropium, Olodaterol, Fluticasone propionate - Pulmonary Disease, Chronic Obstructive | Phase 4 | Completed | Boehringer Ingelheim | 302 | 2017-08-14 | 2020-04-16 |
| Study of REGN3500 and Dupilumab in Patients With Asthma REGN3500, Dupilumab, Placebo - Asthma, Allergic | Phase 1 | Completed | Regeneron Pharmaceuticals | 32 | 2017-06-15 | 2020-01-18 |
Showing 20 of 125. Sign in to see all of them.
Asthma (49) · Rhinitis, Allergic, Seasonal (16) · Pulmonary Disease, Chronic Obstructive (13) · Rhinitis, Allergic (13) · Rhinitis, Allergic, Perennial (9) · Eosinophilic Esophagitis (6) · Disease (4) · Hypersensitivity (4) · Bronchiolitis Obliterans Syndrome (3) · Eosinophilia (3) · Esophageal Diseases (3) · Esophagitis (3) · Gastroenteritis (3) · Gastrointestinal Diseases (3) · Hematologic Diseases (3)
GlaxoSmithKline (30) · Boehringer Ingelheim (8) · Teva Branded Pharmaceutical Products R&D, Inc. (8) · Optinose US Inc. (5) · Dey (4) · Meda Pharmaceuticals (4) · Ellodi Pharmaceuticals, LP (3) · Organon and Co (3) · Pfizer (3) · Research in Real-Life Ltd (3) · University of Chicago (3) · University of Dundee (3) · Egalet Ltd (2) · Intech Biopharm Ltd. (2) · Milton S. Hershey Medical Center (2)
United States (69) · United Kingdom (17) · Germany (14) · Poland (11) · Canada (9) · Russia (9) · Ukraine (9) · Australia (8) · Netherlands (8) · Hungary (7) · South Africa (7) · Spain (7) · Belgium (5) · Bulgaria (5) · Mexico (5)
Lewis M Fredane, MD (3) · Elliot Israel, MD (2) · Marc E. Rothenberg, M.D., Ph.D. (2) · Robert M Naclerio, MD (2) · W K Chang, M.D (2) · Adam Wanner, MD (1) · Alison Chisholm, MSc (1) · Brian Lipworth, MD, FRCP (1)
PMID 27216137, PMID 36472162, PMID 34753535, PMID 35437059, PMID 20167147, PMID 20197425, PMID 20299628, PMID 20568384, PMID 20674827, PMID 20674829, PMID 20692026, PMID 20920764, PMID 21205715, PMID 23364390, PMID 23706709, PMID 24107462, PMID 24525446, PMID 24768678, PMID 25196117, PMID 25624132, PMID 25705889, PMID 26289742, PMID 26475726, PMID 27066739, PMID 27622699, PMID 27881132, PMID 27937064, PMID 28065396, PMID 28272175, PMID 28540844, PMID 28626983, PMID 28639542, PMID 28763243, PMID 28933971, PMID 29928924, PMID 30053956, PMID 30545350, PMID 32943047, PMID 34000435, PMID 34126278, PMID 35123074, PMID 35942814, PMID 38686450
2015 (3), 2014 (2), 2016 (2), 2017 (1), U10HL064287 (1), U10HL064288 (1), U10HL064295 (1), U10HL064305 (1), U10HL064307 (1), U10HL064313 (1), U10HL074073 (1), U10HL074204 (1), U10HL074206 (1), U10HL074208 (1), U10HL074212 (1)